TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Scius Pharma Support AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
50
|
73
|
89 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-23
|
-26
|
6 |
| EBITDA |
-23
|
-26
|
6 |
| Total assets |
66
|
94
|
143 |
| Current assets |
66
|
94
|
143 |
| Current liabilities |
8
|
11
|
8 |
| Equity capital |
58
|
83
|
134 |
| - share capital |
4
|
5
|
4 |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
87.9%
|
88.3%
|
93.7% |
| Turnover per employee |
50
|
73
|
89 |
| Profit as a percentage of turnover |
-46.0%
|
-35.6%
|
6.7% |
| Return on assets (ROA) |
-34.8%
|
-27.7%
|
4.2% |
| Current ratio |
825.0%
|
854.5%
|
1787.5% |
| Return on equity (ROE) |
-39.7%
|
-31.3%
|
4.5% |
| Change turnover |
-21
|
-16
|
-37 |
| Change turnover % |
-29%
|
-18%
|
-30% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.